Reversing chemoresistance of malignant glioma stem cells using gold nanoparticles
Received 29 August 2012
Accepted for publication 22 October 2012
Published 1 March 2013 Volume 2013:8(1) Pages 689—702
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 5
Anamaria Orza,1,2 Olga Soriţău,3 Ciprian Tomuleasa,3,4 Liliana Olenic,5 Adrian Florea,4 Ovidiu Pana,5 Ioan Bratu,5 Emoke Pall,6 Stefan Florian,3 Dan Casciano,2 Alexandru S Biris2
1Faculty of Chemistry and Chemical Engineering, Babes-Bolyai University, Cluj-Napoca, Romania; 2Center for Integrative Nanotechnology Sciences, University of Arkansas at Little Rock, Little Rock, AR, USA; 3Ion Chiricuta Oncology Institute, Cluj-Napoca, Romania; 4Faculty of General Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; 5National Institute for Research and Development of Isotopic and Molecular Technologies, Cluj-Napoca, Romania; 6Department of Research, University of Agriculture and Veterinary Medicine, Cluj-Napoca, Romania
Abstract: The low rate of survival for patients diagnosed with glioblastoma may be attributed to the existence of a subpopulation of cancer stem cells. These stem cells have certain properties that enable them to resist chemotherapeutic agents and ionizing radiation. Herein, we show that temozolomide-loaded gold nanostructures are efficient in reducing chemoresistance and destroy 82.7% of cancer stem cells compared with a 42% destruction rate using temozolomide alone. Measurements of in vitro cytotoxicity and apoptosis indicate that combination with gold facilitated the ability of temozolomide, an alkylating drug, to alter the resistance of these cancer stem cells, suggesting a new chemotherapy strategy for patients diagnosed with inoperable recurrent malignant glioma.
Keywords: gold nanoparticles, drug delivery, temozolomide therapy, temozolomide stability, cancer stem cells, recurrent high-grade gliomas
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.